MoonLake Immunotherapeutics Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
8.9%projected annual EPS growth
Analyst Coverage
13analysts covering
FY EPS (est.)
-$3.33next fiscal year
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Short-Term Marketable Securities Quarterly357.9MTarget: Sufficient capital to fund operations and planned capital expenditures through the end of 2027
Quarterly Net Loss Quarterly-69.7MTarget: Manageable cash burn aligned with clinical trial progression
Quarterly Research and Development (R&D) Expenses Quarterly-54.5MTarget: Efficient allocation of capital to late-stage clinical trials
Watch Items
- Sonelokimab BLA Submission for Hidradenitis Suppurativa (HS)Trigger: Submission expected by end of September/Q3 2026Action: Monitor FDA acceptance of the BLA package based on existing MIRA, VELA-1, and VELA-2 data
- Phase 3 IZAR-1 Trial Readout in Psoriatic Arthritis (PsA)Trigger: Primary and key secondary endpoint data expected in mid-2026Action: Evaluate clinical efficacy and safety profile of sonelokimab in joint indications
- Phase 3 VELA-TEEN Trial Readout in Adolescent HSTrigger: Primary endpoint readout expected in mid-2026Action: Assess clinical data to support the pediatric/adolescent label expansion strategy
- Phase 3 IZAR-2 Trial Readout in Psoriatic Arthritis (PsA)Trigger: Primary endpoint readout expected in Q4 2026Action: Analyze long-term efficacy and safety data to complete the PsA regulatory package
Research as of 19 Jun 2026